...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Resverlogix Invites Collaborations for use of Apabetalone in Trials and Studies to Combat the Spread of COVID-19 Based on New Research

Re: Recent findings point to BET protein and ACE2 inhibition as possible means to slow and reduce the impact of COVID-19....

posted on Mar 23, 2020 07:20PM

Thanks Jonzo!
Hadn't seen that one before.
Here back at you

re: rvx-297

 http://molpharm.aspetjournals.org/content/92/6/694

 

" RVX-297 suppressed EAE pathology when administered to mice either prophylactically or therapeutically. In addition, the production of multiple cytokines in vivo (Fig. 7) and ex vivo (Table 6) was suppressed by RVX-297. In vivo efficacy was comparable or superior to that of the S1P1 agonist FTY720 (fingolimod), an approved therapeutic agent for the treatment of MS."

Share
New Message
Please login to post a reply